Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Integra LifeSciences Holdings Corp Market Cap
Based on ratings from 6 stock analysts, the Integra LifeSciences Holdings Corp stock price is expected to increase by 2.5% in 12 months. This is calculated by using the average 12-month stock price forecast for Integra LifeSciences Holdings Corp. The lowest target is $38.00 and the highest is $55.00. Please note analyst price targets are not guaranteed and could be missed completely.
IART is a stock in Health Care which has been forecasted to be worth $46.33 as an average. On the higher end, the forecast price is $55.00 USD by david turkaly from JMP Securities and on the lower end IART is forecasted to be $38.00 by robbie marcus from J.P. Morgan.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| matthew taylor Jefferies | Buy | $50.0 | maintained | Feb 5, 2024 |
| vik chopra Wells Fargo | Buy | $49.0 | maintained | Feb 5, 2024 |
| ryan zimmerman BTIG | Hold | None | maintained | Jan 1, 2024 |
| richard newitter Truist Financial | Hold | $46.0 | maintained | Dec 22, 2023 |
| david turkaly JMP Securities | Buy | $55.0 | reiterated | Dec 14, 2023 |
| craig bijou Bank of America Securities | Sell | $40.0 | maintained | Dec 13, 2023 |
| joanne wuensch Citi | Sell | $38.0 | maintained | Dec 11, 2023 |
| kristen stewart C.L. King | Buy | $50.0 | initiatedcoverage | Nov 14, 2023 |
| robbie marcus J.P. Morgan | Sell | $38.0 | maintained | Oct 26, 2023 |
| drew ranieri Morgan Stanley | Sell | $44.0 | downgraded | Aug 24, 2023 |
| steven lichtman Oppenheimer | Buy | $53.0 | maintained | Jul 28, 2023 |
| matthew o'brien Piper Sandler | Hold | $44.0 | maintained | Jun 26, 2023 |
| david toung Argus Research | Hold | None | downgraded | Jun 8, 2023 |
| larry biegelsen Wells Fargo | Hold | $47.0 | maintained | May 24, 2023 |
| jayson bedford Raymond James | Hold | None | maintained | Feb 23, 2023 |
| robert marcus J.P. Morgan | Hold | $75.0 | upgraded | Dec 17, 2021 |
| matt miksic Credit Suisse | Buy | $87.0 | maintained | Nov 3, 2021 |
| anthony petrone Jefferies | Buy | $86.0 | rated | May 20, 2021 |
| shagun singh chadha RBC Capital | Hold | $74.0 | maintained | Apr 29, 2021 |
| brandon henry RBC Capital | Hold | $62.0 | maintained | Oct 25, 2019 |
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
When did it IPO
0
Staff Count
3,722
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. Jan De Witte
Market Cap
$3.52B
In 2023, IART generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that IART's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
PCH-USD
$44.29
AVAV-USD
$123.75
IRTC-USD
$112.17
$12.39
ITRI-USD
$75.4
ACLS-USD
$111.45
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
